Tocilizumab and Corticosteroids Increase Risk of COVID-19-Associated Pulmonary Aspergillosis Development Among Critically Ill Patients
Am J Ther
.
2023 May 1;30(3):e268-e274.
doi: 10.1097/MJT.0000000000001617.
Authors
Mohammed T Awad
1
,
Rajmund Michal Niwinski
2
,
Azizullah Beran
3
,
Chad Tidwell
4
,
Ayman O Soubani
1
Affiliations
1
Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, Detroit, MI.
2
Wayne State University School of Medicine, Detroit, MI.
3
Division of Gastroenterology and Hepatology, Indiana University, Indianapolis, IN.
4
Internal Medicine Department, Wayne State University School of Medicine, Detroit, MI.
PMID:
37278708
DOI:
10.1097/MJT.0000000000001617
No abstract available
Publication types
Letter
MeSH terms
Adrenal Cortex Hormones / adverse effects
COVID-19 Drug Treatment
COVID-19* / complications
Critical Illness / therapy
Humans
Pulmonary Aspergillosis* / drug therapy
Substances
tocilizumab
Adrenal Cortex Hormones